Drug or treatment

Atezolizumab clinical trials

• 105Clinical trials
• 45Countries

Newest trials

All recruiting trials (105)

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• BL-M14D1 with Atezolizumab for extensive-stage small cell lung cancer

  This phase 2 trial tests whether adding BL-M14D1 to atezolizumab helps people with extensive-stage small cell lung cancer live longer or well enough to continue treatment.

  Recruiting Phase 2 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07654400

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• DSP-0390 with Atezolizumab in extensive-stage small cell lung cancer

  This pilot phase Ib study tests whether adding DSP-0390 to maintenance atezolizumab after initial chemo-immunotherapy is safe and shows early signs of activity in people with extensive-stage small cell lung cancer who have not progressed.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07545954

• YSCH-01 alone or with atezolizumab for recurrent glioblastoma

  This will test whether YSCH-01 by itself or together with atezolizumab helps people with recurrent glioblastoma live longer.

  Recruiting Early Phase 1 Huashan Hospital · Shanghai, Shanghai Municipality · NCT07538128

• AI system to predict response to Atezolizumab-Bevacizumab in unresectable liver cancer

  This study looks at whether an artificial intelligence tool can predict how patients with unresectable hepatocellular carcinoma will respond to atezolizumab-bevacizumab.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07495735

• Obrixtamig with atezolizumab, carboplatin, and etoposide for advanced small cell lung cancer

  This trial will test whether adding obrixtamig to atezolizumab plus carboplatin and etoposide helps people with extensive-stage small cell lung cancer live longer.

  Recruiting at 166 sites Phase 3 Boehringer Ingelheim · Mobile, Alabama and 241 other locations · NCT07472517

• Atezolizumab after surgery to prevent NSCLC from coming back

  This trial tests whether giving atezolizumab (with or without hyaluronidase) for one year after complete surgery helps prevent NSCLC from returning compared with observation.

  Recruiting at 145 sites Phase 3 National Cancer Institute (NCI) · Anaheim, California and 144 other locations · NCT07388524

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• Sacituzumab govitecan with atezolizumab or durvalumab as maintenance for extensive-stage small cell lung cancer

  This study tests whether adding sacituzumab govitecan to ongoing atezolizumab or durvalumab can better control tumors in adults with extensive-stage small cell lung cancer after initial platinum-based chemotherapy.

  Recruiting Phase 2 Henry Ford Health System · Detroit, Michigan · NCT07339059

• SX-682 with Atezolizumab for advanced or metastatic NSCLC

  This phase 2 trial tests whether combining SX-682 with atezolizumab can help people with advanced, metastatic, or recurrent NSCLC who have progressed after prior treatments.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07322341

• Bevacizumab followed by atezolizumab versus both together for advanced hepatocellular carcinoma with MASLD

  This test will see if giving bevacizumab first and then atezolizumab works better than giving both at the same time for adults with advanced hepatocellular carcinoma and metabolic-associated steatotic liver disease (MASLD).

  Recruiting Phase 2/3 Eastern Hepatobiliary Surgery Hospital · Shanghai, Shanghai Municipality · NCT07285850

• Atezolizumab subcutaneous: patient satisfaction, effectiveness, and safety in routine care

  This will see if subcutaneous Atezolizumab given in routine care is satisfying, helpful, and safe for people with certain types of lung cancer or advanced liver cancer.

  Recruiting at 92 sites Hoffmann-La Roche · Krems and 91 other locations · NCT07284121

• Real-world first-line atezolizumab for stage IV NSCLC with PD-L1 ≥50% in Türkiye

  This project will see how well first-line atezolizumab works and how safe it is for adults with stage IV non-small cell lung cancer whose tumors have PD-L1 ≥50% and no targetable mutations in routine care in Türkiye.

  Recruiting at 15 sites Antalya Training and Research Hospital · Adana and 24 other locations · NCT07279402

• Using fecal microbiota transplantation to try to restore response to atezolizumab and bevacizumab in people with unresectable hepatocellular carcinoma.

  This will try whether giving a fecal microbiota transplant and then restarting atezolizumab plus bevacizumab can restore treatment response in adults with unresectable HCC who progressed early on those drugs.

  Recruiting Phase 2 IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT07276100

• Trimipramine with atezolizumab and bevacizumab for recurrent glioblastoma

  Researchers will try whether adding the antidepressant trimipramine to the immunotherapy atezolizumab plus bevacizumab helps people with recurrent glioblastoma.

  Recruiting at 7 sites Phase 2 Centre Hospitalier Universitaire Vaudois · Basel, Basel and 6 other locations · NCT07263438

• Carbon ion radiotherapy plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma

  This trial will try adding carbon ion radiotherapy to standard atezolizumab‑bevacizumab treatment for adults with advanced hepatocellular carcinoma to see if it controls tumors better and improves survival.

  Recruiting Phase 2 Yonsei University · Seoul · NCT07246668

• Neoadjuvant TACE plus atezolizumab and bevacizumab for resectable high-risk liver cancer

  This study will try combining TACE with atezolizumab and bevacizumab before surgery to see if it shrinks tumors and reduces the chance of recurrence for people with resectable hepatocellular carcinoma who are at high risk of coming back.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 3 other locations · NCT07239245

• DSP107 plus atezolizumab versus fruquintinib for advanced colorectal cancer

  This test will see if giving DSP107 together with atezolizumab works better and is as safe as fruquintinib for adults with advanced microsatellite-stable colorectal cancer who have already tried standard treatments.

  Recruiting at 18 sites Phase 2 Kahr Medical · Aurora, Colorado and 17 other locations · NCT07235293

• FOLFOX chemotherapy with atezolizumab and bevacizumab after progression on atezolizumab plus bevacizumab for advanced liver cancer

  This trial will test whether giving FOLFOX chemotherapy together with continued atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma whose cancer progressed on prior atezolizumab plus bevacizumab.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07192185

• OTS-412 (recombinant oncolytic vaccinia) with or without hydroxyurea and atezolizumab for treatment‑resistant solid tumors

  This trial will test whether OTS-412, given alone or together with hydroxyurea and/or atezolizumab, is safe and can help people whose solid tumors have stopped responding to standard treatments.

  Recruiting at 2 sites Phase 1 Bionoxx Inc. · Busan and 1 other locations · NCT07190833

• ABBV-706 plus atezolizumab versus standard first-line therapy for extensive-stage small cell lung cancer

  This trial will test whether giving ABBV-706 with atezolizumab is safer or more effective than standard first-line chemo plus atezolizumab in adults with previously untreated extensive-stage small cell lung cancer.

  Recruiting at 70 sites Phase 2 AbbVie · New Haven, Connecticut and 69 other locations · NCT07155174

• Neoadjuvant atezolizumab with carboplatin and paclitaxel followed by atezolizumab maintenance for Stage III non-small cell lung cancer

  This trial tests whether giving atezolizumab with carboplatin and paclitaxel before possible surgery, then continuing atezolizumab afterward, helps people with stage III non-small cell lung cancer stay free of disease progression longer.

  Recruiting at 20 sites Phase 2 Fundación GECP · Alicante, Alicante and 20 other locations · NCT07153445

• Iadademstat with SBRT and atezolizumab for extensive-stage small cell lung cancer

  This phase 1b test checks if adding iadademstat to stereotactic body radiotherapy (SBRT) and the immunotherapy atezolizumab is safe and helps control disease in adults with residual, recurrent, or progressive extensive-stage small cell lung cancer after platinum chemotherapy.

  Recruiting Phase 1 Yale University · New Haven, Connecticut · NCT07113691

• Combining atezolizumab and bevacizumab with Y-90 radioembolization to help people with liver cancer get to transplant

  This trial tests whether adding immunotherapy (atezolizumab plus bevacizumab) to Y-90 radioembolization can help people with hepatocellular carcinoma bridge to or be downstaged for liver transplant.

  Recruiting Phase 4 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07059494

• Neoadjuvant atezolizumab and doxorubicin with preoperative radiation and adjuvant atezolizumab for high‑risk resectable limb and trunk soft tissue sarcoma

  This will test whether adding the immunotherapy atezolizumab to doxorubicin chemotherapy before surgery, with radiation before surgery and more atezolizumab after surgery, can delay relapse in adults with high‑risk, resectable soft tissue sarcoma of the arms, legs, or trunk.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07049848

• Atezolizumab and Bevacizumab before and after surgery for resectable liver cancer

  This study tests whether giving atezolizumab and bevacizumab around surgery can help people with resectable hepatocellular carcinoma see better outcomes.

  Recruiting at 12 sites Phase 2 Fundacion Clinic per a la Recerca Biomédica · Badalona, Barcelona and 11 other locations · NCT07018947

• Combining cytokine-induced memory-like natural killer cells with atezolizumab for relapsed or refractory AML

  This trial will test whether giving cytokine-induced memory-like natural killer cells together with atezolizumab is safe and might help adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07011004

• Irpagratinib plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma with FGF19 overexpression

  This trial will test whether adding irpagratinib to atezolizumab and bevacizumab helps people with advanced or unresectable hepatocellular carcinoma whose tumors overexpress FGF19.

  Recruiting Phase 2 Asan Medical Center · Seoul and 2 other locations · NCT07010497

• Preventing esophageal varices in liver cancer patients treated with specific medications

  This study is testing whether treating liver cancer patients with specific medications can help prevent the worsening of esophageal varices and reduce the risk of bleeding.

  Recruiting Tanta University · Tanta, Gharbyea · NCT06961526

• Tarlatamab with carboplatin/etoposide and atezolizumab for EGFR‑mutant lung adenocarcinoma that changed into small cell lung cancer

  This trial tests whether adding tarlatamab to standard platinum‑etoposide chemotherapy and atezolizumab helps patients whose EGFR‑mutant lung adenocarcinoma has transformed into small cell lung cancer.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gangnam-gu · NCT06830694

• Stereotactic body radiotherapy with atezolizumab and bevacizumab for HCC with major portal vein thrombosis

  This test tries adding SBRT to atezolizumab plus bevacizumab to see if it helps people with HCC and major portal vein thrombosis who have not progressed after two cycles of systemic therapy.

  Recruiting at 2 sites Phase 2 Chinese University of Hong Kong · Hong Kong and 1 other locations · NCT06823375

• Preventive endoscopic banding for high-risk esophageal varices in people with hepatocellular carcinoma starting atezolizumab plus bevacizumab

  This study will test whether doing preventive endoscopic banding of high-risk esophageal varices can reduce bleeding in people with hepatocellular carcinoma who are starting atezolizumab plus bevacizumab.

  Recruiting Phase 2 Asan Medical Center · Seoul, Song-pa · NCT06819566

• Testing valemetostat with atezolizumab for lung cancer treatment

  This study is testing a new combination of medications, valemetostat and atezolizumab, to see if it can safely help people with extensive-stage small cell lung cancer who have had some success with earlier treatments.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06807632

• Real-life experience with immunotherapy for liver cancer treatment

  This study is testing new combinations of immunotherapy treatments for liver cancer to see how well they work and how safe they are for patients.

  Recruiting at 16 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Torrette, AN and 23 other locations · NCT06806579

• Treatment for PD-L1-positive metastatic triple-negative breast cancer

  This study is testing a new treatment plan that combines two drugs after initial therapy to see if it helps people with PD-L1-positive metastatic triple-negative breast cancer live longer without their cancer getting worse.

  Recruiting Phase 2 Japan Breast Cancer Research Group · Koto-ku, 3-8-31, Tokyo · NCT06793553

• Combination therapy for hepatocellular carcinoma using atezolizumab, bevacizumab, and memantine

  This study is testing a new combination of three medications to see if it can help people with advanced liver cancer feel better and improve their quality of life.

  Recruiting at 2 sites Phase 2 Inova Health Care Services · Fairfax, Virginia and 1 other locations · NCT06789757

• Combining Atezolizumab with Chemotherapy for Small Cell Lung Cancer

  This study is testing whether adding atezolizumab to chemotherapy can help people with extensive-stage small cell lung cancer feel better and have fewer side effects compared to chemotherapy alone.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT06780826

• Combining radiotherapy with immunotherapy for extensive small cell lung cancer

  This study is testing if combining radiation therapy with a type of immunotherapy can help people with extensive small cell lung cancer live longer after their initial treatment.

  Recruiting Phase 2 Regina Elena Cancer Institute · Rome, Rome · NCT06771518

• Combination treatment for metastatic colorectal cancer patients

  This study is testing if adding Atezolizumab to the usual treatment for patients with advanced colorectal cancer can help them live longer without their cancer getting worse.

  Recruiting at 24 sites Phase 3 Gruppo Oncologico del Nord-Ovest · Brescia, BS and 23 other locations · NCT06733038

• Combining radiotherapy and immunotherapy for advanced liver cancer before transplant

  This study is testing if combining radiation therapy with immunotherapy can help people with advanced liver cancer get better and qualify for a liver transplant.

  Recruiting Phase 1/2 University Health Network, Toronto · London, Ontario and 1 other locations · NCT06725121

• Investigating BNT327 with chemotherapy for untreated small-cell lung cancer

  This study is testing whether a new treatment called BNT327, combined with standard chemotherapy, can help people with untreated extensive-stage small-cell lung cancer feel better compared to another treatment option.

  Recruiting at 188 sites Phase 3 BioNTech SE · Tucson, Arizona and 224 other locations · NCT06712355

• Evaluating RZ-001 with Valganciclovir and Atezolizumab/Bevacizumab for Liver Cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it is safe and effective for patients with a specific type of the disease.

  Recruiting at 9 sites Phase 1/2 Rznomics, Inc. · Busan and 8 other locations · NCT06695026

• Atezolizumab with cyclophosphamide and vinorelbine for metastatic triple-negative breast cancer

  This trial will test whether adding atezolizumab to the chemotherapy drugs cyclophosphamide and vinorelbine helps people with PD-L1–positive metastatic triple-negative breast cancer who are starting first-line treatment after prior PD-1/PD-L1 therapy.

  Recruiting at 2 sites Phase 2 European Institute of Oncology · Monza, Monza and 4 other locations · NCT06690840

• Combining atezolizumab with chemotherapy for relapsed extensive-stage small cell lung cancer

  This study is testing if adding an immunotherapy drug called atezolizumab to standard chemotherapy can help people with relapsed extensive-stage small cell lung cancer live longer and feel better.

  Recruiting at 2 sites Phase 2 Gruppo Oncologico Italiano di Ricerca Clinica · Aviano (PN) and 24 other locations · NCT06663098

• Comparing two treatments for extensive-stage small cell lung cancer

  This study is testing a new treatment combination for extensive-stage small cell lung cancer to see if it works better and is safer than the standard treatment.

  Recruiting at 18 sites Phase 3 Bristol-Myers Squibb · Daphne, Alabama and 182 other locations · NCT06646276

• Combining dTACE-HAIC with Bevacizumab and Atezolizumab for treating large liver cancer

  This study is testing a new combination treatment for people with large liver cancer to see if it works better than current options for those who can't have surgery.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06609863

• Using advanced MRI to assess treatment response in liver cancer patients

  This study is testing a special type of MRI to see if it can help doctors understand how well new treatments are working for people with liver cancer.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06605664

• Combining atezolizumab and bevacizumab with stereotactic body radiotherapy for advanced liver cancer

  This study is testing if combining two cancer drugs with a specific type of radiation therapy can help people with advanced liver cancer feel better and improve their treatment outcomes.

  Recruiting Yonsei University · Yongin-si · NCT06595108

• Combining Yttrium-90 with Capecitabine and Atezolizumab for Liver Metastases from Colorectal Cancer

  This study is testing a new treatment that combines a special type of radiation with two medications to see if it can help people with advanced colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Brown University · Providence, Rhode Island · NCT06555133

• Combining Atezolizumab with Radiation and Surgery for Lung Recurrence of Osteosarcoma

  This study is testing whether combining a new immune therapy called Atezolizumab with radiation and surgery can help people with lung recurrences of osteosarcoma feel better and improve their chances of recovery.

  Recruiting Phase 1 Emory University · Atlanta, Georgia · NCT06492954

• Treatment of advanced solid tumors with VET3-TGI immunotherapy

  This study is testing a new cancer treatment called VET3-TGI to see if it can safely target and kill cancer cells in patients with advanced solid tumors, either by injecting it directly into the tumors or giving it through an IV.

  Recruiting at 7 sites Phase 1 KaliVir Immunotherapeutics · Los Angeles, California and 6 other locations · NCT06444815

• Pemigatinib plus atezolizumab and bevacizumab for advanced FGFR2‑fusion cholangiocarcinoma

  This trial tests whether adding pemigatinib to atezolizumab and bevacizumab can help control advanced cholangiocarcinoma in patients whose tumors have an FGFR2 fusion.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06439485

• Evaluating a new treatment for extensive stage-small cell lung cancer

  This study is testing a new treatment combining ifinatamab deruxtecan and atezolizumab, with or without carboplatin, to see if it can help people with extensive stage-small cell lung cancer feel better and improve their treatment results.

  Recruiting at 55 sites Phase 1/2 Daiichi Sankyo · Birmingham, Alabama and 57 other locations · NCT06362252

• Combining Atezolizumab and Bevacizumab with Photon Radiotherapy for Liver Cancer

  This study is testing if combining two cancer drugs, atezolizumab and bevacizumab, with radiation therapy can help people with liver cancer that can't be surgically removed live longer and feel better.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06339424

• Evaluating LB-LR1109 for treating solid tumors

  This study is testing a new treatment called LB-LR1109 to see how safe it is and how well it works for people with advanced solid tumors that can't be treated with standard options.

  Recruiting Phase 1 LG Chem · Fairfax, Virginia · NCT06332755

• Valemetostat with atezolizumab and bevacizumab for advanced hepatocellular carcinoma

  This will test whether adding the oral drug valemetostat to atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma who have not received prior systemic therapy.

  Recruiting Phase 1/2 University of Alabama at Birmingham · Birmingham, Alabama · NCT06294548

• Combining iadademstat with immunotherapy for advanced small cell lung cancer

  This study is testing whether adding a new drug called iadademstat to standard immunotherapy can help people with advanced small cell lung cancer live longer without their disease getting worse.

  Recruiting at 33 sites Phase 1/2 National Cancer Institute (NCI) · Duarte, California and 42 other locations · NCT06287775

• Using atezolizumab before surgery for HPV-related throat cancer

  This study is testing if giving the immunotherapy drug atezolizumab before surgery can help people with HPV-related throat cancer by seeing how well it works and how safe it is.

  Recruiting Phase 2 Emory University · Atlanta, Georgia · NCT06254911

• Atezolizumab plus bevacizumab for recurrent advanced hepatocellular carcinoma in liver transplant recipients

  This trial will see if the cancer drug combination atezolizumab plus bevacizumab is safe for adults whose hepatocellular carcinoma has recurred after a liver transplant.

  Recruiting at 10 sites Phase 2 Assistance Publique - Hôpitaux de Paris · Clichy and 9 other locations · NCT06254248

• ProAgio treatment for advanced pancreatic cancer

  This study is testing a new treatment called ProAgio combined with standard chemotherapy to see if it helps people with advanced pancreatic cancer feel better and live longer.

  Recruiting Phase 1 ProDa BioTech, LLC · Birmingham, Alabama · NCT06182072

• Combining two drugs to treat rare genitourinary tumors

  This study is testing whether a combination of two drugs can help adults with rare and aggressive genitourinary tumors feel better and improve their treatment options.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06161532

• Combining Atezolizumab and Bevacizumab with Proton Radiotherapy for Liver Cancer

  This study is testing if combining two cancer-fighting drugs with a type of targeted radiation can help people with advanced liver cancer that can't be surgically removed feel better and live longer.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06133062

• Combining total body irradiation with chemotherapy and immunotherapy for extensive stage lung cancer

  This study is testing if adding total body radiation to standard chemotherapy and immunotherapy can help people with advanced small cell lung cancer live longer and feel better.

  Recruiting Phase 1/2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT06110572

• Identifying biomarkers for atezolizumab in recurrent glioblastoma

  This study is testing if a new immune therapy called atezolizumab can help people with recurrent glioblastoma who have low levels of tumor mutations.

  Recruiting at 3 sites Phase 2 Duke University · San Francisco, California and 3 other locations · NCT06069726

• Testing lower doses of atezolizumab for cancer treatment

  This study is testing whether lower doses of atezolizumab can effectively treat adults with advanced cancer while causing fewer side effects.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06066138

• Evaluating Glofitamab Alone or with Other Treatments for Richter's Transformation

  This study is testing if a new treatment called Glofitamab, alone or with other medications, can help people with Richter's Transformation from Chronic Lymphocytic Leukemia feel better.

  Recruiting at 5 sites Phase 2 Dana-Farber Cancer Institute · Atlanta, Georgia and 4 other locations · NCT06043674

• Combining LB-100 and Atezolizumab for Metastatic Colorectal Cancer

  This study is testing whether combining two drugs, LB-100 and atezolizumab, can help people with advanced colorectal cancer respond better to treatment.

  Recruiting Phase 1 The Netherlands Cancer Institute · Amsterdam, North Holland · NCT06012734

• Combination treatment for advanced liver cancer with portal vein tumor invasion

  This study is testing a new combination treatment for advanced liver cancer with portal vein tumor invasion to see if it helps patients live longer compared to standard treatment.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangzhou · NCT05984511

• Neoadjuvant immunochemotherapy for resectable colon cancer

  This study is testing a new combination of immunotherapy and chemotherapy before surgery to see if it helps people with early-stage colon cancer.

  Recruiting Phase 2 Baylor College of Medicine · Houston, Texas · NCT05870800

• Using atezolizumab to treat cancers with high mutation rates or specific genetic deficiencies

  This study is testing if atezolizumab can help treat adults and kids with certain types of cancers that have a lot of genetic changes or specific genetic issues.

  Recruiting at 23 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT05770102

• Combining a PD-L1 inhibitor and dendritic cell vaccination with chemotherapy for malignant pleural mesothelioma

  This study is testing a new treatment that combines a PD-L1 blocker and a special vaccine with chemotherapy to see if it helps people with a type of lung cancer called malignant pleural mesothelioma.

  Recruiting at 3 sites Phase 1/2 University Hospital, Antwerp · Edegem, Antwerp and 2 other locations · NCT05765084

• Predicting early treatment response in advanced liver cancer

  This study is testing if a new way to combine two cancer treatments can help people with advanced liver cancer respond better than using each treatment alone.

  Recruiting Seoul National University Hospital · Seoul · NCT05763277

• Combining TACE with Atezolizumab and Bevacizumab for Unresectable Liver Cancer

  This study is testing whether a new treatment that combines a type of chemotherapy with two immunotherapy drugs can help people with liver cancer that can't be surgically removed feel better compared to current treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05751343

• Combination therapy for extensive stage small cell lung cancer

  This study is testing a new combination treatment for patients with extensive stage small cell lung cancer who have responded to their initial therapy to see if it helps them stay healthy longer.

  Recruiting at 16 sites Phase 1/2 Genprex, Inc. · Lone Tree, Colorado and 16 other locations · NCT05703971

• Fecal microbiota transfer to overcome resistance to atezolizumab/bevacizumab in liver cancer

  This will test whether adding fecal microbiota transfer to standard atezolizumab/bevacizumab helps adults with advanced hepatocellular carcinoma respond better.

  Recruiting Phase 2 University Hospital Heidelberg · Heidelberg, Baden-Wurttemberg and 6 other locations · NCT05690048

• Combining Bevacizumab with Chemoimmunotherapy for Advanced Lung Cancer with Liver Metastases

  This study is testing whether adding a drug called bevacizumab to a combination of chemotherapy and another treatment can help people with advanced lung cancer that has spread to the liver live longer and feel better.

  Recruiting at 3 sites Phase 2 Cedars-Sinai Medical Center · Los Angeles, California and 2 other locations · NCT05588388

• Combining ONC201 and Atezolizumab for treating obesity-related endometrial cancer

  This study is testing a new treatment for advanced or recurrent endometrial cancer in obese women by combining two drugs, ONC201 and atezolizumab, to see if it helps manage their cancer better.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT05542407

• Combining vismodegib and atezolizumab for treating resistant ovarian cancer

  This study is testing a new combination of two drugs, vismodegib and atezolizumab, to see if they can help people with ovarian cancer that hasn't responded to standard treatments.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT05538091

• Combining a cancer vaccine with immunotherapy for liver cancer treatment

  This study is testing a new cancer vaccine combined with immunotherapy to see if it can help people with advanced liver cancer who haven't had treatment before.

  Recruiting at 11 sites Phase 2 Centre Hospitalier Universitaire de Besancon · Besançon and 13 other locations · NCT05528952

• Using multi-omics to predict treatment response in liver cancer patients

  This study is testing if a combination of two drugs can help liver cancer patients who have had surgery stay cancer-free longer by looking at their unique biological traits.

  Recruiting at 5 sites Phase 2 National Cancer Centre, Singapore · Singapore and 5 other locations · NCT05516628

• Combining radiation therapy with immunotherapy for liver cancer

  This study is testing a new treatment that combines radiation therapy with immunotherapy drugs to see if it can help people with advanced liver cancer who can't have surgery.

  Recruiting Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT05488522

• Combination therapy with atezolizumab and tiragolumab for solid tumors

  This study is testing a new combination treatment using two immune-boosting drugs for people with solid tumors, like melanoma and head and neck cancers, to see if it can help them fight their cancer better than current treatments.

  Recruiting Phase 2 University Medical Center Groningen · Groningen · NCT05483400

• Combining cyclophosphamide, sorafenib, bevacizumab, and atezolizumab for children and young adults with relapsed solid tumors

  This will test whether giving atezolizumab and bevacizumab every three weeks together with daily cyclophosphamide and dose‑adjusted sorafenib is safe and can shrink relapsed or hard‑to‑treat solid tumors in children and young adults, including fibrolamellar carcinoma.

  Recruiting Phase 1/2 St. Jude Children's Research Hospital · Germantown, Tennessee and 1 other locations · NCT05468359

• Combining Atezolizumab with radiation therapy for brain tumors

  This study is testing if combining a cancer drug called Atezolizumab with radiation therapy can help people with newly diagnosed brain tumors feel better and improve their treatment results.

  Recruiting Early Phase 1 Stony Brook University · Stony Brook, New York · NCT05423210

• Combining Atezolizumab and Selinexor for Alveolar Soft Part Sarcoma

  This study is testing if a combination of two drugs, atezolizumab and selinexor, can help shrink tumors in patients with advanced alveolar soft part sarcoma better than standard treatments.

  Recruiting at 12 sites Phase 2 National Cancer Institute (NCI) · Los Angeles, California and 12 other locations · NCT05333458

• Combining Atezolizumab with Etoposide and Platinum for Small Cell Bladder Cancer

  This study is testing if a new combination of atezolizumab, etoposide, and platinum-based chemotherapy can help people with advanced small cell bladder cancer respond better to treatment before surgery.

  Recruiting at 2 sites Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Washington D.C., District of Columbia and 1 other locations · NCT05312671

• Combining atezolizumab with a multi-kinase inhibitor for advanced liver cancer treatment

  This study is testing if adding atezolizumab to either cabozantinib or lenvatinib can help people with advanced liver cancer live longer and feel better compared to just taking the multi-kinase inhibitor alone.

  Recruiting at 10 sites Phase 2 Academic and Community Cancer Research United · Scottsdale, Arizona and 15 other locations · NCT05168163

• Combining Atezolizumab, Bevacizumab, and Radiation for Unresectable Liver Cancer

  This study is testing if combining two cancer-fighting drugs with targeted radiation can help people with liver cancer that can't be surgically removed.

  Recruiting at 2 sites Phase 1 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT05096715

• Combining immunotherapy with chemotherapy for advanced neuroendocrine cancer

  This study is testing if adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with advanced neuroendocrine cancer live longer and feel better.

  Recruiting at 243 sites Phase 2/3 National Cancer Institute (NCI) · Anchorage, Alaska and 265 other locations · NCT05058651

• Combining atezolizumab and cabozantinib for treating recurrent or metastatic osteosarcoma in adolescents and young adults

  This study tests if combining two medications, atezolizumab and cabozantinib, can help adolescents and young adults with recurrent or metastatic osteosarcoma live longer and feel better.

  Recruiting at 2 sites Phase 2 M.D. Anderson Cancer Center · Boston, Massachusetts and 1 other locations · NCT05019703

• Combining Atezolizumab and Tivozanib for Treating Certain Cancer Types

  This study is testing a new combination of two cancer drugs, Atezolizumab and Tivozanib, to see if they can help people with tough-to-treat cancers like bile duct, gallbladder, breast, and neuroendocrine tumors.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT05000294

• Atezolizumab treatment for patients with malignant pleural mesothelioma after surgery

  This study is testing if the drug atezolizumab can help prevent cancer from coming back in patients with malignant pleural mesothelioma after they've had surgery.

  Recruiting at 2 sites Phase 3 Gruppo Oncologico Italiano di Ricerca Clinica · Meldola, ITAòY and 18 other locations · NCT04996017

• Combining three medications for advanced kidney cancer treatment

  This study is testing a combination of three medications to see if they can help people with advanced kidney cancer feel better and live longer.

  Recruiting at 6 sites Phase 2 National Cancer Institute (NCI) · La Jolla, California and 12 other locations · NCT04981509

• Using temozolomide and atezolizumab for advanced small cell lung cancer

  This study is testing if a combination of two drugs, temozolomide and atezolizumab, can help people with advanced small cell lung cancer live longer and feel better.

  Recruiting at 5 sites Phase 2 Big Ten Cancer Research Consortium · Chicago, Illinois and 4 other locations · NCT04919382

• Predicting response to immunotherapy and chemotherapy in lung cancer

  This study is testing if a special immune profile can help predict how well patients with lung cancer will respond to a combination of treatments before surgery.

  Recruiting Phase 2 University Hospital Heidelberg · Heidelberg, BaWü · NCT04865250

• Treatment for premenopausal women with metastatic breast cancer

  This study is testing whether a new treatment combining talazoparib with atezolizumab works better than talazoparib alone for premenopausal women with a specific type of metastatic breast cancer.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gannam-gu · NCT04819243

• Comparing atezolizumab plus bevacizumab to TACE for liver cancer treatment

  This study is testing if a combination of two drugs, atezolizumab and bevacizumab, works better than a standard treatment called TACE for people with intermediate-stage liver cancer.

  Recruiting at 72 sites Phase 3 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Graz and 71 other locations · NCT04803994

• Combining tocilizumab and atezolizumab for advanced lung cancer after previous treatments

  This study is testing if combining two medications, tocilizumab and atezolizumab, can help adults with advanced lung cancer that hasn't improved with previous treatments.

  Recruiting Phase 1/2 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT04691817

• Targeted treatments for recurrent endometrial cancer

  This study is testing different targeted treatments, with or without an immune therapy, to see if they can help people with recurrent endometrial cancer based on their tumor's genetic makeup.

  Recruiting Phase 1/2 Alliance Foundation Trials, LLC. · Duarte, California and 20 other locations · NCT04486352

• Combining Atezolizumab and Pirfenidone for Advanced Lung Cancer

  This study is testing if adding pirfenidone to atezolizumab can help people with advanced lung cancer who have already been treated feel better and fight their cancer more effectively.

  Recruiting Phase 1/2 University of Kansas Medical Center · Fairway, Kansas and 1 other locations · NCT04467723

• Atezolizumab and sacituzumab govitecan to prevent recurrence in triple-negative breast cancer

  This trial tests whether combining sacituzumab govitecan with atezolizumab can prevent cancer from coming back in people with triple-negative breast cancer who have residual disease after pre-surgery chemotherapy and detectable circulating tumor DNA.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · San Francisco, California and 6 other locations · NCT04434040

• Effects of Atezolizumab on Cancer Patients with Sensitive Tumor DNA or RNA

  This study is testing if atezolizumab can help cancer patients with certain tumor types that show they might respond well to the treatment.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia and 1 other locations · NCT04273061

• Atezolizumab-based therapy for men with localized prostate cancer before surgery

  This study is testing a new immunotherapy treatment for men with localized prostate cancer to see if it helps their immune system fight the cancer before they have surgery.

  Recruiting at 2 sites Phase 2 University of California, San Francisco · San Francisco, California and 1 other locations · NCT03821246

• Stereotactic Body Radiation Therapy with Immunotherapy for Oligometastatic Sarcoma

  This study is testing if combining a special type of radiation therapy with an immunotherapy drug can help people with oligometastatic soft tissue sarcoma live longer and feel better compared to just using radiation alone.

  Recruiting at 4 sites Phase 2 Centre Antoine Lacassagne · Bordeaux and 16 other locations · NCT03548428

Quick answers

How many clinical trials of Atezolizumab are recruiting right now?

105, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 45 countries. The most sites are in United States (52 trials), China (15 trials), Italy (14 trials), South Korea (13 trials), Spain (10 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 51, Phase 1/2: 14, Phase 1: 14, Phase 3: 8. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →